Fundz

Calidi Biotherapeutics

San Diego, California, United States · Biotechnology, Health Care, Therapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped tech

Key facts

Headquarters
San Diego, California, United States
Employees
31
Industries
Biotechnology, Health Care, Therapeutics
Status
Public (CLDI)
Website
calidibio.com
LinkedIn
Company page

Recent activity at Calidi Biotherapeutics

  • : SEC 8-K (7.01):
  • : SEC 8-K (8.01): On September 25, 2026, Calidi Biotherapeutics, Inc. issued a press release concerning the company's intention to submit a compliance plan to the NYSE American. This plan aims to address compliance issues with the exchange's continued listing standards. The filing indicates potential risks related to the company's ability to raise capital and meet other requirements for compliance. The forward-looking statements included highlight uncertainties that could materially affect the company's future performance, making this a crucial communication for shareholders and stakeholders.
  • : SEC 8-K (1.01): On September 17, 2026, Calidi Biotherapeutics, Inc. entered into a stock purchase agreement with certain accredited investors for a registered direct offering. The Company agreed to issue and sell 1,025,640 shares of its common stock at a price of $1.17 per share, totaling approximately $1.2 million in gross proceeds. The offering officially closed on September 21, 2026. This transaction represents a significant financing event for Calidi Biotherapeutics, potentially enhancing its liquidity and financial position.
  • : SEC 8-K (7.01):
  • : SEC 8-K (1.01):
  • : SEC 8-K (5.02):
  • : SEC 8-K (1.01): On May 28, 2026, Calidi Biotherapeutics, Inc. entered into a material definitive agreement by issuing an amended and restated warrant to purchase up to 17,391,304 shares of its common stock at an exercise price of $0.23 to an accredited investor. This new warrant supersedes a previous warrant issued on May 6, 2026, and includes conditions such as requiring shareholder approval for exercise and increasing the minimum vesting acquisition amount from $500,000 to $1,000,000. Additionally, it extends the vesting termination date from July 8, 2026, to September 30, 2026. The transaction was conducted under Section 4(a)(2) of the Securities Act, ensuring compliance with securities regulations.
  • : SEC 8-K (7.01):
  • : SEC 8-K (1.01): On May 6, 2026, Calidi Biotherapeutics, Inc. entered into a material definitive agreement by issuing a warrant to purchase up to 17,391,304 shares of its common stock at an exercise price of $0.23. This transaction occurred in a private placement to an accredited investor and allows the holder the option to acquire up to $4.0 million of Common Stock, subject to certain vesting conditions. The warrant is set to be first exercisable on September 8, 2026, and is to be made in accordance with the Securities Act of 1933. This agreement indicates strategic movement towards capitalizing on investment opportunities while adhering to federal securities regulations.
  • : SEC 8-K (5.02): On March 29, 2026, Mr. Allan J. Camaisa informed the Board of Directors of Calidi Biotherapeutics, Inc. that he intends to allow his Director position to expire at the Company's upcoming 2026 annual stockholder meeting. This decision did not arise from any disagreements related to company operations or policies. In relation to this change, effective April 1, 2026, the Board reduced its size from six to five directors as part of the adjustments following Mr. Camaisa's decision. Additionally, Scott Leftwich was appointed to the Audit Committee on the same day, marking a significant governance shift within the Board.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Calidi Biotherapeutics funding history

DateRoundAmount
Aug 2025Post-IPO Equity$6.9M
Jun 2024Venture$5.5M
Mar 2024Venture$3.5M
Feb 2024Venture$33K
Jan 2024Venture$1.0M

Leadership

  • Allan Camaisa, CEO & Chair of the Board
  • Scott Leftwich, Cofounder and Vice Chairman of Board of Directors
  • Andrew Jackson, Chief Financial Officer
  • Guy Travis Clifton, Chief Medical Officer

Verified email and direct lines for Calidi Biotherapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Calidi Biotherapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Companies similar to Calidi Biotherapeutics

About Calidi Biotherapeutics: questions and answers

What does Calidi Biotherapeutics do?

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped tech

Where is Calidi Biotherapeutics headquartered?

Calidi Biotherapeutics is headquartered in San Diego, California, United States.

How many employees does Calidi Biotherapeutics have?

Calidi Biotherapeutics has about 31 employees.

Has Calidi Biotherapeutics raised funding?

Yes. Fundz has recorded 5 funding events for Calidi Biotherapeutics. The most recent, Post-IPO Equity of $6.9M, was in Aug 2025.

Who leads Calidi Biotherapeutics?

Allan Camaisa is a CEO & Chair of the Board at Calidi Biotherapeutics.

What is the latest news on Calidi Biotherapeutics?

On Oct 24, 2025, SEC 8-K (7.01):

Is Calidi Biotherapeutics a public company?

Yes. Calidi Biotherapeutics is publicly traded under the ticker CLDI.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Calidi Biotherapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.